Largest biotech companies by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech companies ranked by total liabilities, at SAR 307.3B, ahead of Gilead Sciences (SAR 136.6B) and Biogen (SAR 41.9B). Figures as of 18 Nov 2026, 17:47 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSAR 307.3B
- Median
- SAR 2.6B
- Combined market value
- SAR 3.16T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SAR 307.3B | SAR 905.8B | SAR 1,674.67 | 2.50% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SAR 136.6B | SAR 787.6B | SAR 634.99 | 0.57% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | SAR 41.9B | SAR 139.7B | SAR 945.36 | 0.49% up | 49% up | ||
| 4 | ModernaMRNA · Health Care | SAR 13.8B | SAR 307.9B | SAR 760.87 | 1.91% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | SAR 11.5B | SAR 78.3B | SAR 315.80 | 0.79% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | SAR 9.4B | SAR 38.4B | SAR 186.20 | 0.22% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | SAR 9.3B | SAR 41.4B | SAR 362.76 | 0.77% up | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SAR 5.2B | SAR 61.7B | SAR 609.80 | 2.02% down | 20% up | ||
| 9 | argenxARGX · Health Care | SAR 5.1B | SAR 223.2B | SAR 3,548.86 | 0.15% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | SAR 3.8B | SAR 26.9B | SAR 25.24 | 7.51% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | SAR 3.2B | SAR 41.4B | SAR 647.12 | 6.38% up | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | SAR 2.7B | SAR 129.8B | SAR 600.22 | 1.64% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | SAR 2.6B | SAR 63.3B | SAR 259.49 | 0.99% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | SAR 1.8B | SAR 42.9B | SAR 273.00 | 0.21% up | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SAR 1.3B | SAR 15.3B | SAR 157.84 | 4.81% up | 21% down | ||
| 16 | VaxcytePCVX · Health Care | SAR 1.2B | SAR 35.1B | SAR 221.48 | 0.60% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | SAR 1.1B | SAR 17.4B | SAR 107.54 | 0.63% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SAR 728.3M | SAR 24B | SAR 366.40 | 0.91% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | SAR 633.6M | SAR 30.1B | SAR 441.79 | 5.16% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | SAR 612M | SAR 39.2B | SAR 458.71 | 0.63% up | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | SAR 595.6M | SAR 21.7B | SAR 177.57 | 5.01% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | SAR 428.5M | SAR 34.9B | SAR 1,177.63 | 5.16% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | SAR 391.7M | SAR 26.1B | SAR 126.15 | 1.26% up | 43% up | ||
| 24 | CG OncologyCGON · Health Care | SAR 146.3M | SAR 27.3B | SAR 306.10 | 3.38% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech companies rank first by total liabilities?
Amgen (SAR 307.3B), Gilead Sciences (SAR 136.6B) and Biogen (SAR 41.9B) are the top three of the 24 biotech companies ranked by total liabilities as of 18 Nov 2026, 17:47 UTC.
How many biotech companies are in this ranking?
24 are ranked by total liabilities.
What are these biotech companies worth together?
The 24 biotech companies ranked by total liabilities have a combined market value of SAR 3.16T as of 18 Nov 2026, 17:47 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.